2-pyrrol-3-yl-ethanol | 22186-59-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 2-pyrrol-3-yl-ethanol
• 英文别名: 3-(hydroxyethyl)-pyrrole；3-(β-Hydroxy-ethyl)-pyrrol, 2--ethanol；3-(β-hydroxy-ethyl)-pyrrol；Pyrrole-3-ethanol；2-(1H-pyrrol-3-yl)ethanol
• CAS: 22186-59-0
• 化学式: C₆H₉NO
• mdl: MFCD12964681
• 分子量: 111.144
• InChiKey: LHDAMAKAICZPOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  36
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-pyrrol-3-yl-ethanol 在 正丁基锂 、 potassium tert-butylate 作用下， 以 乙醚 、 二甲基亚砜 为溶剂， 生成 [3-(2-Hydroxy-ethyl)-1-methyl-1H-pyrrol-2-yl]-phenyl-methanone
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Ketorolac Analogs

  摘要：

  DOI：

  10.3987/com-01-s(k)44
• 作为产物：
  描述：

  2-[1-(triisopropylsilanyl)-1H-pyrrol-3-yl]ethanol 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 生成 2-pyrrol-3-yl-ethanol
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Ketorolac Analogs

  摘要：

  DOI：

  10.3987/com-01-s(k)44

文献信息

• Pyrroles substituted by oligonucleotides
  申请人：Mandrand Bernard

  公开号：US20060189555A1

  公开（公告）日：2006-08-24

  The invention relates to novel pyrrole derivatives of the formula (I) which make it possible to immobilize and address oligonucleotides by electropolymerization. Said invention also relates to thus produced electroactive polymers and to methods for using them for detecting, identifying and dosing analytes in a sampe. (I) wherein R 1 is one type of oligonucleotide, Y is S or O, X is a spacer arm selected from —(CH 2 )—O—, —(CH 2 )PO—[(CH 2 ) 2 —O] q —, —(CH2 )r ; —CO—NR—(CH 2)r -0-, —CH 2r —NCH 3 —(CH 2 ) r —O—, —CH 2 ) r CO—NR′—[CH 2 ) 2 —O] s —, —(CH 2 ) r NCH 3 [(CH 2 ) 2 —O]S—, R′ is H or CH 3 , n is an integer number ranging from 1 to 5, p is an integer number ranging from 1 to 2, q is an integer number ranging from 1 to 4, r is an integer number ranging from 1 to 3, r′ is an integer number ranging from 1 to 3, s is an integer number ranging from 1 to 3, n, p, q, r, r′ and s are identical or different, a pyrrole cycle is substituted in a position 2, 3, 4 or 5.

  该发明涉及公式（I）的新型吡咯衍生物，可以通过电聚合固定和寻址寡核苷酸。该发明还涉及因此产生的电活性聚合物，以及使用它们用于检测、鉴定和定量样品中的分析物的方法。在公式（I）中，R1是一种类型的寡核苷酸，Y是S或O，X是从—（CH2）—O—、—（CH2）PO—（（CH2）2—O）q—、—（CH2）r；—CO—NR—（CH2r）-O-、—CH2r—NCH3—（CH2）r—O—、—CH2rCO—NR′—（CH2）2—O）s—、—（CH2）rNCH3（（CH2）2—O）S—中选择的间隔臂，R′是H或CH3，n是从1到5的整数，p是从1到2的整数，q是从1到4的整数，r是从1到3的整数，r′是从1到3的整数，s是从1到3的整数，n、p、q、r、r′和s是相同或不同的，吡咯环在位置2、3、4或5上被取代。
• Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin
  申请人：Canonne Frédéric

  公开号：US20090314660A1

  公开（公告）日：2009-12-24

  The invention relates to novel electropolymerisable monomers which are to be polymerised in an aqueous solution and comprise: an electropolymerisable pattern selected from acetylene, pyrrols, thiophenes, indols, anilines, azines, p-phenylene vinylenes, p-phenylenes, pyrenes, furanes, selenophenes, pyrridazines, carbazoles, acrylates, methacrylates and the derivatives thereof, and a metalloporphyrine which is substituted by at least two ionised or ionisable entities in an aqueous solution. The invention also relates to a method for the polymerisation of such monomers, to the electroactive probe that can be obtained by the polymerisation of such monomers, and to a method for detecting a target ligand in a biological sample using one such electroactive probe.

  本发明涉及一种新型电聚合单体，该单体可在水溶液中聚合，包括：从乙炔、吡咯、噻吩、吲哚、苯胺、吡啶、对苯乙烯、对苯二甲酸酯、甲基丙烯酸酯及其衍生物中选择的电聚合图案，以及在水溶液中被至少两个离子化或可离子化实体取代的金属卟啉。本发明还涉及一种这样的单体的聚合方法，可以通过聚合这样的单体获得电活性探针，以及使用这样的电活性探针在生物样品中检测目标配体的方法。
• Quinazoline Derivative
  申请人：Mizutani Takashi

  公开号：US20080275069A1

  公开（公告）日：2008-11-06

  This invention provides a compound or its pharmaceutically-acceptable salt of formula (I) wherein R 1 represents a lower alkyl group et al; R 2 and R 3 are same and different and represents hydrogen atm et al; R 4 represents the substituent of the formula (I) et al; X 1 represents NH, O or S; Y represents N or C; Ar is a divalent substituent derived from aryl et al, by removing two hydrogen atoms therefrom; the ring A represents a 5- or 6-membered heteroaryl group; this compounds has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for preventive or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.

  本发明提供了式（I）的化合物或其药学上可接受的盐，其中R1代表较低的烷基等；R2和R3相同或不同，分别代表氢原子等；R4代表式（I）的取代基等；X1代表NH、O或S；Y代表N或C；Ar是由芳基衍生的二价取代基等，通过去除其中的两个氢原子而得到；环A表示5-或6-成员杂芳基基团；这些化合物具有组胺H3受体拮抗作用或组胺H3受体反向激动剂作用，并且对于预防或治疗代谢系统疾病、循环系统疾病或神经系统疾病是有用的。
• Novel Benzoxathiine Derivative
  申请人：Mizutani Takashi

  公开号：US20100168156A1

  公开（公告）日：2010-07-01

  Disclosed is a compound represented by the formula (I) below and a pharmaceutically acceptable salt thereof. This compound is useful for treatment of obesity, diabetes and the like. [In the formula (I), Ar represents a benzene ring or the like; X 1 represents a nitrogen atom, a sulfur atom or the like; R1 represents an aryl group or the like; X 2 represents a group represented by the following formula (II): (wherein R 4 and R 5 respectively represent a lower alkyl group or the like, and m represents a number of 2-4) or the like; one of X and Y represents an oxygen atom and the other represents a sulfanyl group or the like; and X 3 -X 6 respectively represent —CH—, a nitrogen atom or the like.

  揭示了一种由下式（I）表示的化合物及其药学上可接受的盐。该化合物可用于治疗肥胖症、糖尿病等疾病。[在式（I）中，Ar代表苯环或类似物；X1代表氮原子、硫原子或类似物；R1代表芳基或类似物；X2代表由以下式（II）表示的基团：（其中R4和R5分别表示低碳基或类似物，m表示2-4的数）或类似物；X和Y中的一个代表氧原子，另一个代表硫基或类似物；X3-X6分别表示-CH-，氮原子或类似物。
• QUINAZOLINE DERIVATIVE
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1757594A1

  公开（公告）日：2007-02-28

  This invention provides a compound or its pharmaceutically-acceptable salt of formula (I) wherein R1 represents a lower alkyl group et al; R2 and R3 are same and different and represents hydrogen atm et al; R4 represents the substituent of the formula (II) et al; X1 represents NH, O or S; Y represents N or C; Ar is a divalent substituent derived from aryl et al, by removing two hydrogen atoms therefrom; the ring A represents a 5- or 6-membered heteroaryl group; this compounds has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for preventive or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.

  本发明提供了一种式 (I) 的化合物或其药学上可接受的盐 其中 R1 代表低级烷基等；R2 和 R3 相同或不同，代表氢大气等；R4 代表式（II）的取代基等； 该化合物具有组胺-H3 受体拮抗作用或组胺-H3 受体反拮抗作用，可用于预防或治疗代谢系统疾病、循环系统疾病或神经系统疾病。